Expertise in
40
conditions

Dr. Jondavid Pollock

Radiation Oncology
WVU Medicine Wheeling Hospital
1 Medical Park, 
Wheeling, WV 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
40
conditions
WVU Medicine Wheeling Hospital
1 Medical Park, 
Wheeling, WV 

Overview

Jondavid Pollock is a Radiation Oncologist practicing medicine in Wheeling, West Virginia.

Dr. Pollock is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Laryngeal Cancer, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 13 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in WV

Hospital Affiliations

Wheeling Hospital, Inc
Reynolds Memorial Hospital
Barnesville Hospital Association, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WVU Medicine Wheeling Hospital
1 Medical Park, Wheeling, WV 26003
Other Locations
Colon & Rectal Clinic LLC
40 Medical Park, Wheeling, WV 26003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: March 05, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
View 9 Less Clinical Trials

12 Total Publications

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Sushil Beriwal
Radiation Oncology
Expertise in
17
conditions
Dr. Sushil Beriwal
Radiation Oncology

West Penn Hosp Outpatient SVCS Allegheny

314 E North Ave, 
Pittsburgh, PA 
 (45.2 miles away)
412-359-3400
Languages Spoken:
English
See accepted insurances

Sushil Beriwal is a Radiation Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Beriwal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Vaginal Cancer, Vulvar Cancer, Cervical Cancer, Vulvectomy, and Orchiectomy.

Expertise in
10
conditions
Dr. Grgur Miric
Radiation Oncology
Expertise in
10
conditions
Dr. Grgur Miric
Radiation Oncology

Wetzel County Hospital Association

3 E Benjamin Dr, 
New Martinsville, WV 
 (27.5 miles away)
304-455-8080
Languages Spoken:
English
See accepted insurances

Grgur Miric is a Radiation Oncologist practicing medicine in New Martinsville, West Virginia. Dr. Miric is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Prostatectomy.

Expertise in
11
conditions
Dr. John A. Vargo
Radiation Oncology
Expertise in
11
conditions
Dr. John A. Vargo
Radiation Oncology

UPMC Hillman Cancer Center

300 Halket Street, 
Pittsburgh, PA 
 (46.3 miles away)
412-641-4600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Austin Vargo IV, MD, is a radiation oncologist specializing in breast cancer and gynecologic malignancies, including image-based brachytherapy and stereotactic radiotherapy. Dr. Vargo is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Vaginal Cancer, Cervical Cancer, Endometrial Cancer, Pancreaticoduodenectomy, and Gamma Knife Radiosurgery. Dr. Vargo is board certified in American Board Of Radiology. Dr. Vargo is currently accepting new patients.

Frequently Asked Questions about Dr. Jondavid Pollock

How do I make an appointment with Dr. Jondavid Pollock?

You can book an appointment with Dr. Jondavid Pollock by calling their office at 304-243-3490. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jondavid Pollock a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jondavid Pollock is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jondavid Pollock specialize in?

While Dr. Jondavid Pollock is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Laryngeal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Jondavid Pollock participate in research or clinical trials?

Yes. Dr. Jondavid Pollock has published 12 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Jondavid Pollock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jondavid Pollock accept my insurance?

Dr. Jondavid Pollock accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 304-243-3490 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pollock's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 22 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile